PND58 Quality of Life of Patients With Parkinson’s Disease And Other Neurodegenerative Disorders  by Chekani, F. et al.
A288  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
OBJECTIVES: Cystic Fibrosis (CF) is a life-limiting, genetic disorder that has a tre-
mendous impact on patient’s quality of life (QoL). The goal of this review is to sum-
marize QoL literature in CF and identify instruments utilized to capture QoL data in 
adult patients. METHODS: A comprehensive literature search using PRISMA guide-
lines was conducted from January 2010 to October 2014 using electronic databases 
such as PubMed, Scopus, CINAHL, and Cochrane Reviews. Studies assessing physical, 
psychological, social and spiritual impact on patients with CF were identified. The 
QoL instruments from the studies were identified and a review of their psycho-
metric properties in CF was conducted. The search strategy was limited to studies 
conducted in adult population. Full-text, published articles in the United States and 
Europe were included in the final review. RESULTS: A total of 14 QoL studies in CF 
which utilized 6 validated instruments were identified. Three instruments were dis-
ease-specific (CFQ-R, CF-QOL, and a single item measure) and the remaining three 
were generic instruments (SF-36, EQ-5D, and UK-SIP). CFQ-R was used in 11 studies, 
whereas 3 studies used the CF-QoL. Some important factors that influenced QoL 
in CF were pain, lung function, self-esteem, and ethnicity. Psychometric validation 
included validity (discriminant, convergent, and concurrent validity) and reliability 
testing. Reliability of the instruments was found to be within appropriate ranges 
(CFQ-R: Cronbach’s alpha ≥ 0.70; CF-QOL: Test-Retest > 0.8; and Generic instruments: 
Internal Consistency > 0.8). CONCLUSIONS: Clinical outcomes, patient perception, 
and demographic variables were found to influence QoL in adult CF patients. CFQ-R 
is the most commonly reported QoL instrument in CF. Also, the time constraint 
physicians face in using QoL assessment in clinical practice can be addressed by 
the recently developed single-item, CF-specific QoL questionnaire. Overall, CF has a 
negative impact on the physical, mental, and social aspects of patient’s life.
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OBJECTIVES: Multiple sclerosis (MS) is an autoimmune and inflammatory demy-
elinating disease of the central nervous system, often characterized by relapsing 
episodes of neurologic impairment followed by remissions (relapsing remitting MS). 
In about a third of MS patients, the disease evolves into a progressive course (progres-
sive MS). The objective of this study was to evaluate how health-related quality of life 
(HRQL) was taken into consideration in the evaluation of MS products approved by 
the FDA and the EMA since 1995. METHODS: The websites of the FDA and the EMA 
were explored to identify all MS products approved. All labels and corresponding 
clinical reviews (FDA), summary of product characteristics (SmPC) and assessments 
reports (EMA) were manually retrieved and reviewed for HRQL evaluation. RESULTS: 
Twelve different products (11 INN) were approved: nine by both agencies, one only 
by the EMA, and two only by the FDA. For the products approved by both agencies, 
the same clinical studies were submitted. HRQL was evaluated in seven products. In 
only one case, HRQL evaluation was mentioned, i.e., in the SmPC of interferon beta-1b 
(“No benefit, attributable to […] in quality of life (as measured by FAMS – Functional 
Assessment of MS: Treatment Outcomes Index) was seen”). There was no HRQL men-
tion in the corresponding FDA label for the same product. In four products HRQL was 
evaluated with generic measures (e.g., SF-36 or SF-12). In most cases, it was considered 
as a tertiary /exploratory endpoint. In three products (alemtuzumab, natalizumab, and 
teriflunomide), statistical differences in HRQL endpoints were seen (measured by the 
FAMS and/or the SF-36), but not reported in labels/SmPCs. CONCLUSIONS: HRQL is 
not considered as a key endpoint in the evaluation of MS products. A patient-focused 
drug development initiative in MS could be helpful to enhance development and use 
of HRQL MS-specific measures in clinical trials.
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OBJECTIVES: Spinal muscular atrophy (SMA), the most common fatal genetic dis-
ease among children, is not included in current U.S. mandatory newborn screening 
panel. We assessed how much, if anything, people would pay for testing their new-
borns for SMA, and how test preferences varied depending on immediate treatment 
implications. METHODS: We conducted a population-based willingness-to-pay 
(WTP) online survey. Respondents were asked to imagine being parents of a new-
born. Each respondent was presented with two sets of hypothetical scenarios follow-
ing the SMA screening test: current standard of care (SOC, no treatment available) 
and one of three randomly-assigned treatment scenarios (new treatment available 
to improve functioning, survival, or both). We used a double-bounded, dichotomous-
choice bidding game to elicit WTP for the SMA test, and performed a two-part model 
to estimate median and mean WTP values. RESULTS: 982 adults completed the 
survey. Most people (79%) would prefer to test their newborns for SMA, given cur-
rent SOC. A greater proportion (85%-87%) would pay for the test if SMA treatment 
existed. People expressed a WTP for the test information even without treatment 
(median: $142; mean: $253), and a higher amount if SMA treatment were available 
(median: $161-$182; mean: $270-$297). WTP was highest for scenarios in which 
treatment were available to improve both functioning and survival of the new-
born. Individuals with higher income were more likely to prefer and pay more for 
the test. CONCLUSIONS: Our findings highlight preferences for the SMA newborn 
screening test under various treatment scenarios. Most people would prefer and 
would be willing to pay for the test information, even in the absence of direct treat-
ment options. People perceived the SMA test more valuable if treatment were avail-
able to improve the newborn’s functioning and survival. Future clinical studies are 
needed to determine how early detection may impact long-term patient outcomes.
review of published peer-reviewed studies. METHODS: A literature search was per-
formed in “MEDLINE” and “EMBASE” using search terms “quality of life”, “neuromyeli-
tis optica”, and “Devic’s”. The search was limited to English language. All studies that 
got published before November 2014 were retrieved. Studies that included patients 
with NMO and reported use of validated QoL instrument were considered eligible for 
qualitative analysis. Two independent researchers were involved in study selection 
and data extraction. RESULTS: A total of seven studies met the inclusion criteria. 
All the studies were conducted in different countries: The United states of America, 
United Kingdom, France, Japan, and Argentina. The number of patients included in 
the studies ranged from 18-50. The common QoL instruments used included: Short 
form-36 and different pain severity scores. Three studies used MS patients as the 
comparator while two compared the data with normal subjects. Most studies reported 
that QoL is lower in NMO patients as compared to the ones suffering from MS and is 
much worse than normal subjects. The lower QoL score corresponded with higher 
pain scores in NMO patients as compred to MS patients. CONCLUSIONS: Our review 
showed that NMO patients are associated with higher levels of pain and lower QoL 
scores than MS patients. However, available evidence seems to be insufficient and 
more research is warrented in this context.
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OBJECTIVES: This study compared the quality of life including Physical Component 
Summary (PCS), Mental Component Summary (MCS), Activities of Daily Living (ADL) 
and Instrumental Activities of Daily Living (IADL) in patients with Parkinson’s dis-
ease and other neurodegenerative conditions. METHODS: The study used data from 
2002-2011 Medical Expenditure Panel Survey (MEPS), a nationally representative 
survey of households in the United States, to assess the measures of quality of life 
in neurodegenerative patients. Multivariate regression was used to examine the 
effect of neurodegenerative conditions on PCS, MCS, ADL and IADL after controlling 
for various sociodemographic and clinical characteristics. RESULTS: The weighted 
study population included 320,464 patients with Parkinson’s disease and 476,200 
patients with other neurodegenerative conditions. Participants were aged between 
19 and 85 years (mean = 74.32, SD = 11.36). In unadjusted models, the mean PCS 
was lower in patients with Parkinson’s disease [33.66 (32.81-34.50)] compared to 
other neurodegenerative disorders [35.31 (34.19-36.42)]; however the mean MCS was 
higher in Parkinson patients [45.30 (44.44-46.17)] compared to other neurodegenera-
tive patients [43.93 (42.99-44.87)]. The adjusted PCS in Parkinson’s disease was 2.43 
(95% CI= 0.72, 4.15) points lower than other neurodegenerative conditions. Patients 
with Parkinson’s disease were less likely to seek help for instrumental activities 
(IADL) than other neurodegenerative disorders [OR= 0.68 (0.50, 0.93)]; however the 
ADL was not significantly different in Parkinson’s disease in comparison to other 
neurodegenerative conditions [OR= 0.91 (0.64, 1.28)]. Comorbidities including car-
diovascular diseases, diabetes and cancer were also associated with decline in the 
quality of life among patients with Parkinson’s disease as well as other neurodegen-
erative conditions. CONCLUSIONS: The study found that, patients with Parkinson’s 
disease had lower PCS and were less likely to seek help for IADL when compared to 
other neurodegenerative conditions. The study findings suggest differences among 
neurodegenerative conditions across various dimensions of quality of life measures.
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OBJECTIVES: About 5-10% of the total Parkinson’s population are diagnosed from 
the ages of 21-45 and thus characterized as having Young-Onset Parkinson’s Disease 
(YOPD). Since YOPD is diagnosed during the most productive years of a patient’s life, the 
disease can potentially have a larger impact on quality of life (QoL), in part due to the 
unique psychosocial issues younger patients face. The goal of the review is to (i) identify 
QoL instruments utilized in YOPD and (ii) describe the studies that have utilized these 
instruments. METHODS: A systematic literature search based on PRISMA guidelines 
was conducted from 2004 to 2014 using electronic databases such as Pubmed, Medline, 
Cochrane, and Ovid. QoL instruments validated in the general population as well as 
those validated in Parkinson’s Disease (PD) were included in this review. The search 
was limited to studies using the English language. Studies conducted exclusively on PD 
patients diagnosed after age 50 and review studies, were excluded. RESULTS: A total 
of 10 QoL instruments were identified (5 disease-specific, 1 condition-specific, and 4 
generic). PD-specific instruments included the Parkinson’s Disease Questionnaire-39 
and the Parkinson’s Impact Scale. Although frequently utilized in YOPD patients, all 
instruments were validated in either regular-onset PD patients (initial diagnosis greater 
than 45 years of age) or the general population. The literary search did not yield any 
YOPD-specific QoL instruments. CONCLUSIONS: Different experiences, emotions, and 
psychological issues exist between YOPD and regular-onset PD. Yet, QoL instruments 
validated in PD were commonly utilized in YOPD. Thus, there is a need to create YOPD-
specific QoL instruments to capture the impact of this condition on young patients. 
In addition, the development of new YOPD-specific instruments may allow clinicians 
the opportunity to better understand the complexity of problems in YOPD patients to 
guide appropriate care of their unique condition.
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